irbesartan
Selected indexed studies
- Irbesartan (a comprehensive profile). (Profiles Drug Subst Excip Relat Methodol, 2021) [PMID:33461698]
- Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. (J Exp Clin Cancer Res, 2023) [PMID:37143164]
- Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. (N Engl J Med, 2001) [PMID:11565517]
_Worker-drafted node — pending editorial review._
Connections
irbesartan is a side effect of
Sources
- Irbesartan (a comprehensive profile). (2021) pubmed
- Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. (2023) pubmed
- Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. (2001) pubmed
- [Irbesartan]. (1998) pubmed
- Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. (2004) pubmed
- The cost-effectiveness of irbesartan for hypertension. (2015) pubmed
- Drug interactions with irbesartan. (2001) pubmed
- Irbesartan and hydrochlorothiazide association in the treatment of hypertension. (2009) pubmed
- Irbesartan: an updated review of its use in cardiovascular disorders. (2000) pubmed
- [Irbesartan in clinical practice]. (2012) pubmed